GenomOncology's GO Clinical Workbench selected by UH to launch clinical cancer product

Oct 27 2014

GenomOncology today announced that University Hospitals (UH) Case Medical Center and UH Seidman Cancer Center (Cleveland, Ohio) have selected the company's GO Clinical Workbench^TM to launch a clinical cancer product. UH will leverage the GO Clinical Workbench for workflow management from raw sequencing data through delivery of an actionable clinical report for oncologists.

UH, the second largest employer in Northeast Ohio with 25,000 employees, serves the needs of patients through an integrated network of 15 hospitals, 26 outpatient centers and primary care physician offices in 15 counties. Its main campus includes UH Case Medical Center, UH Rainbow Babies & Children's Hospital, UH MacDonald Women's Hospital, and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University.

"Cancer research not only advances cancer treatment, it also provides a source of hope and help to patients for whom other treatments have failed," said Joseph Willis, MD, Division Chief, Clinical Pathology at UH Case Medical Center. "Coupling our research efforts with the powerful analytics provided by the GO Clinical Workbench will allow us to quickly translate scientific findings into the highest quality patient care."

GenomOncology's GO Clinical Workbench streamlines the use of Next Generation Sequencing (NGS) data and allows molecular pathology laboratories to produce an actionable clinical report using the molecular profile of an individual patient's tumor. The platform is configured to each clinical laboratory's specific needs with systems integration (LIMS, EMR, etc.), setting of quality control and annotation parameters, and design of the resultant clinical report.

"GenomOncology is honored to have our GO Clinical Workbench selected by University Hospitals, one of the nation's leading health care systems," said Manuel Glynias, President and CEO of GenomOncology. "We are confident that our robust technology platform and onsite support will allow University Hospitals to continue to provide the most advanced care to their patients."

SOURCE GenomOncology